Symbol="IKT"
AssetType="Common Stock"
Name="Inhibikase TherapeuticsÂ Inc"
Description="Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia."
CIK="1750149"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA, GA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="13144000"
EBITDA="-18121884"
PERatio="None"
PEGRatio="None"
BookValue="4.892"
DividendPerShare="0"
DividendYield="0"
EPS="-4.09"
RevenuePerShareTTM="0.033"
ProfitMargin="0"
OperatingMarginTTM="-128.25"
ReturnOnAssetsTTM="-0.342"
ReturnOnEquityTTM="-0.603"
RevenueTTM="141930"
GrossProfitTTM="-8258499"
DilutedEPSTTM="-4.09"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.402"
AnalystTargetPrice="27"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="219.63"
PriceToBookRatio="0.492"
EVToRevenue="2.748"
EVToEBITDA="0.733"
Beta="0.747"
num_52WeekHigh="6.94"
num_52WeekLow="2.21"
num_50DayMovingAverage="3.221"
num_200DayMovingAverage="3.676"
SharesOutstanding="5300000"
DividendDate="None"
ExDividendDate="None"
symbol="IKT"
open="2.45"
high="2.45"
low="2.21"
price="2.25"
volume="13245.00"
latest_trading_day="2023-08-16"
previous_close="2.34"
change="-0.09"
change_percent="-3.8034%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="89"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="11"
Volume_recent_avg="123024"
Change_recent_avg="-0.01"
Delta_recent_avg="0.12"
Variance_recent_avg="0.06"
Change_ratio_recent_avg="-0.61"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="11"
Aroon_momentum_negative="89"
image_negative_thumbnail_id_1="170"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0006.jpeg"
image_negative_thumbnail_id_2="490"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0115.jpeg"
image_neutral_thumbnail_id_1="432"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Neutral_Landscape_0019.jpeg"
image_neutral_thumbnail_id_2="585"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0014.jpeg"
image_positive_thumbnail_id_1="689"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0019.jpeg"
image_positive_thumbnail_id_2="695"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0013.jpeg"
image_professor_thumbnail_id_1="1192"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0026.jpeg"
image_professor_thumbnail_id_2="1180"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
